Helicobacter

Papers
(The H4-Index of Helicobacter is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta‐analysis of RCTs58
Gastric Helicobacter pylori infection does not contribute to extraoral halitosis and its eradication cannot achieve substantial reduction of halitosis53
Issue Information49
UreBimmunodominant epitope‐specificCD8+T‐cell responses were beneficial in reducing gastric symptoms inHelicobacter pylori‐infected individuals40
Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis38
Low‐dose or high‐dose amoxicillin in vonoprazan‐based dual therapy for Helicobacter pylori eradication? A systematic review and meta‐analysis38
DNA starvation/stationary phase protection protein of Helicobacter pylori as a potential immunodominant antigen for infection detection38
A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy o37
Proteomic Profiling of Extracellular Vesicles Reveals Potential Biomarkers for Helicobacter pylori Infection and Gastric Cancer34
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp‐EuReg)31
Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China31
30
A “new” option in Helicobacter pylori eradication: High‐dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting30
Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines30
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first‐line regimen for Helicobacter pylori eradication: A randomized controlled trial29
Low compliance to post‐screening recommendations in a family‐based Helicobacter pylori screening and treatment program: A prospective cohort study28
Innate Immunity in Helicobacter pylori Infection and Gastric Oncogenesis28
Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicro28
Issue Information27
Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan—A 20‐year longitudinal follow‐up27
Issue Information27
Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school‐aged children: A randomized non‐blinded trial26
Managing Helicobacter pylori as an Infectious Disease: Implementation of Antimicrobial Stewardship26
Nationwide survey ofHelicobacter pyloriseropositivity and gastric atrophy in Zambia26
Roles of Gastric Non‐Helicobacter pylori Helicobacter Species in Gastric Disease Development: A Review24
Letter to the Editor regarding the article: “Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy”24
0.061102151870728